Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor

Check, Jerome H.; Check, Diane; Poretta, Trina

doi:10.21873/anticanres.13301

Cited by 26 publications

(36 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The decrease of weight gain in the animals was due to implantation of tumor cells. In according to the literature, several clinical studies of mifepristone in patients with breast cancer ( 58 ), meningioma ( 59 ), and non-small cell lung cancer ( 60 ) have demonstrated that mifepristone has tolerable side effect, including nausea, lethargy, anorexia, fatigue, and hot flashes; even when mifepristone has been taken daily for long periods of time, it has mild adverse effects; therefore, the long-term administration of mifepristone may be feasible and well tolerated; we proposed in the near future to test this possibility and to evaluate whether mifepristone offers greater benefits during tumor recurrence. According to the current results, mifepristone could possibly contribute to the modulation of tumor relapse in glioblastoma by decreasing the levels of VEGF, MGMT, and P-gp.…”

Section: Discussionmentioning

confidence: 99%

Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide

et al. 2020

View full text Add to dashboard Cite

Glioblastoma, the most common primary central nervous system tumor, is characterized by extensive vascular neoformation and an area of necrosis generated by rapid proliferation. The standard treatment for this type of tumor is surgery followed by chemotherapy based on temozolomide and radiotherapy, resulting in poor patient survival. Glioblastoma is known for strong resistance to treatment, frequent recurrence and rapid progression. The aim of this study was to evaluate whether mifepristone, an antihormonal agent, can enhance the effect of temozolomide on C6 glioma cells orthotopically implanted in Wistar rats. The levels of the vascular endothelial growth factor (VEGF), and P-glycoprotein (P-gp) were examined, the former a promoter of angiogenesis that facilitates proliferation, and the latter an efflux pump transporter linked to drug resistance. After a 3-week treatment, the mifepristone/temozolomide regimen had decreased the level of VEGF and P-gp and significantly reduced tumor proliferation (detected by PET/CT images based on 18F-fluorothymidine uptake). Additionally, mifepristone proved to increase the intracerebral concentration of temozolomide. The lower level of O6-methylguanine-DNA-methyltransferase (MGMT) (related to DNA repair in tumors) previously reported for this combined treatment was herein confirmed. After the mifepristone/temozolomide treatment ended, however, the values of VEGF, P-gp, and MGMT increased and reached control levels by 14 weeks post-treatment. There was also tumor recurrence, as occurred when administering temozolomide alone. On the other hand, temozolomide led to 100% mortality within 26 days after beginning the drug treatment, while mifepristone/temozolomide enabled 70% survival 60–70 days and 30% survived over 100 days, suggesting that mifepristone could possibly act as a chemo-sensitizing agent for temozolomide.

show abstract

Section: Discussionmentioning

confidence: 99%

Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Single agent mifepristone, not only in a short period of time improved low PO2 and severe hyponatremia in a woman with very advanced probable small cell lung cancer but provided a marked extension of a high quality of life (28). For non-small cell lung cancer (NSCLC) mifepristone provided marked palliative benefits, and increased length of life, in patients with chemotherapy and immunotherapy resistant advanced lung cancers that were either not associated with any tumor markers, or were associated with the programmed death factor-1, or the epidermal growth factor receptor mutation (29)(30)(31). All 4 of these NSCLC patients had brain metastasis, and all 4 progressed despite standard chemotherapy (29)(30)(31).…”

Section: Discussionmentioning

confidence: 99%

“…For non-small cell lung cancer (NSCLC) mifepristone provided marked palliative benefits, and increased length of life, in patients with chemotherapy and immunotherapy resistant advanced lung cancers that were either not associated with any tumor markers, or were associated with the programmed death factor-1, or the epidermal growth factor receptor mutation (29)(30)(31). All 4 of these NSCLC patients had brain metastasis, and all 4 progressed despite standard chemotherapy (29)(30)(31). One of the patients progressed despite addition of nivolumab prior to mifepristone therapy, and two progressed despite treatment with the thirdgeneration tyrosine kinase inhibitor, osimertinib (30,31).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life

Check

Srivastava

et al. 2020

Anticancer Res

Self Cite

View full text Add to dashboard Cite

“…Thus, treatment with mifepristone may be a method to stop metastatic lung cancer which was positive for the PD-L1. 31,32…”

Section: Use Of Orally Administered Steroidsmentioning

confidence: 99%

Novel Oral Drug Delivery Systems for Steroids: Overview and Recent Updates

Ganapa¹,

Mhatre²,

Raut³

et al. 2020

IJPER

View full text Add to dashboard Cite

This review summarises the oral route of drug delivery of steroids. Oral drug delivery is widespread owing to its non-invasive nature which complements high patient compliance. This article summarises the problems associated with oral delivery of steroids including bioavailability. In this review, a brief description of the novel types of drug delivery systems of steroids such as microspheres, nanoparticles, solid lipid nanoparticles, multimatrix tablets, pellet technology, liposomes are presented. The review also presents the latest innovations and advances that have been achieved in recent years.

show abstract

Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor

Cited by 26 publications

References 20 publications

Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide

Mifepristone as a Potential Therapy to Reduce Angiogenesis and P-Glycoprotein Associated With Glioblastoma Resistance to Temozolomide

Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life

Novel Oral Drug Delivery Systems for Steroids: Overview and Recent Updates

Contact Info

Product

Resources

About